Abbott Laboratories (NYSE:ABT) reported new FreeDM2 trial results on its FreeStyle Libre continuous glucose monitoring system for people with Type 2 diabetes using basal insulin. The company also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results